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1	 <4	 <10	 <0.3	
2	 4–8	 12–69	 0.4-2.4	
3	 8–10	 60–275	 2.1-9.5	
4	 10–20	 142–515	 4.9-17.9	
5	 20-25	 319-775	 11.1-26.9	
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In	 the	 majority	 of	 patients	 with	 DP	 the	 neuroendocrine	 pathophysiology	 and	 its	 genetic	
regulation	 remain	 unclear.	 Linkage	 analysis	 and	 targeted	 sequencing	 strategies	 appear	 to	
	 70	





























post	 fertilization	 (hpf)	with	 the	development	of	nearly	all	major	vertebrate	organ	systems	
firmly	 established.	 GnRH	 neurons	 develop	 in	 a	 parallel	 manner	 to	 in	 humans	 and	 other	
mammals,	with	migration	from	their	origin	in	the	olfactory	area	to	the	hypothalamus	during	
the	 first	 5	 days	 post	 fertilisation	 (dpf).	 Zebrafish	 models,	 particularly	 the	 transgenic	
(Tg)	GnRH3:EGFP	zebrafish	line,	in	which	GnRH3	neurons	express	EGFP,	have	been	utilised	to	
investigate	 the	 mechanism	 of	 action	 of	 several	 important	 regulators	 of	 GnRH	 neuronal	
migration,	including	SDF-1,	Netrin	(230)	and	NELF	(74).	In	contrast,	pubertal	onset	in	zebrafish	
is	a	relatively	late	event.	Gonadal	differentiation	is	completed	around	35	dpf	in	females	and	




Puberty	 and	 the	 timing	 of	 pubertal	 onset	 has	 been	 studied	 using	 several	 other	 model	
organisms,	 ranging	 from	 primates	 to	 sheep	 and	 even	 the	 worm	 Caenorhabditis	 elegans.	
Primates	 have	 a	 similar	 pattern	 of	 HPG	 axis	 activity	 to	 humans	 with	 a	 period	 of	 relative	
quiescence	 from	 late	 infancy	 until	 the	 onset	 of	 puberty,	 and	 hypothalamic	 control	 of	 the	
	 72	
pituitary-gonadal	axis	through	GnRH	was	first	established	in	higher	primates	(232).	Primate	










a	 more	 precocious	 age	 of	 pubertal	 onset	 in	 the	 developed	 world.	 Previous	 studies	 have	
suggested	 that	up	 to	80%	of	 the	 inheritance	of	pubertal	 timing	 is	 genetically	determined.	
Identification	of	these	critical	alleles	has	not	been	feasible	by	GWAS	alone,	probably	due	to	
their	low	frequency.	
My	 hypothesis	 was	 that	 discovery	 of	 novel	 genetic	 regulators	 of	 pubertal	 timing	may	 be	
achieved	through	next	generation	sequencing	of	subjects	with	pubertal	timing	at	the	tail	ends	
of	the	normal	population	distribution,	with	an	extreme	phenotype	inherited	via	one	or	a	few	
genetic	 variants.	Our	 cohort	 of	 pedigrees	 affected	with	 familial	 self-limited	DP	provides	 a	













regulation	between	 late	pubertal	 timing	 in	patients	with	 self-limited	DP	and	 the	 timing	of	
puberty	 in	 the	 general	 population.	 I	 examined	 the	 loci	 identified	 in	 previous	 studies	 of	
pubertal	timing	via	GWAS	of	AAM,	for	any	overlapping	genetic	candidates	identified	by	the	



















































































































































Segregation with trait 
‘Multiple family’ filtering 
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A	 quantitation	 assay	 is	 a	 real-time	PCR	assay	which	measures	 the	 amount	of	 nucleic	 acid	
during	each	amplification	cycle	of	the	PCR.	For	this	purpose,	fluorescent	SYBR	Green	I	dye	
chemistry	was	used.	This	uses	 the	SYBR	Green	 I	dye	which	binds	 to	double	stranded	DNA	
formed	during	PCR.	During	the	PCR,	DNA	polymerase	amplifies	the	target	sequence,	which	
creates	the	PCR	products	(amplicons).	The	SYBR	Green	I	dye	then	binds	to	each	new	copy	of	








































(QuikChange	 II	 Site-Directed	 Mutagenesis	 Kit,	 Agilent	 Technologies,	 Stockport,	 UK,	 see	
















step	of	30	 sec	at	95°C,	 cycling	was	performed	 (for	18	 cycles	 for	 control	 and	12	 cycles	 for	
reaction)	at	95°C	for	30	sec,	55°C	for	1	min	and	68°C	for	1	min/kb	plasmid	length.	Following	
temperature	cycling,	the	reaction	was	placed	on	ice	for	2	minutes	to	cool	to	≤37°C.	1	µl	of	the	








were	 picked	 and	 grown	 in	 LB	medium-ampicillin	 before	 plasmid	 extraction	 (QIAprep	 spin	
Mini-prep	kit	used	according	 to	 the	manufacturer’s	 instructions,	Qiagen,	Crawley,	UK,	 see	
Appendix	5	for	reagents).	Mutations	were	verified	by	sequencing.		
HEK293	 (sourced	 from	 ATCC,	Middlesex,	 UK)	 were	 transfected	 with	 wild	 type	 or	 mutant	





























































































































































































MO	activities	 in	 zebrafish	 embryos	 include	both	 sequence-specific	RNA	binding	 as	well	 as	
effects	not	associated	with	loss	of	function	of	the	targeted	locus.	The	latter	‘off-target’	effects	
can	be	a	confounding	variable	when	using	MOs	for	the	assignment	of	function	to	sequence	in	








































































































































































































































































































HS6ST1	 4	 3	 3.23E-06	 3.01E-05	
LRRIQ3	 12	 88	 1.66E-07	 4.65E-06	
EAP1	 8	 39	 1.42E-06	 1.99E-05	
IGSF10	 13	 292	 0.0029	 0.020	
SEC24A	 3	 17	 0.0051	 0.029	
ZNF560	 2	 6	 0.00823	 0.038	
FTO	 3	 29	 0.0188	 0.058	
LGR4		 8	 172	 0.0155	 0.058	
CYFIP1	 2	 10	 0.01852	 0.058	
TTF1	 7	 96	 0.023	 0.064	
THBS4	 3	 33	 0.02574	 0.066	
INHA	 3	 39	 0.0384	 0.090	
SYPL2	 5	 114	 0.04472	 0.096	
ELFN2	 2	 22	 0.06745	 0.135	
SETBP1	 2	 25	 0.0829	 0.155	
TBX6	 4	 102	 0.1204	 0.211	
FANCL	 3	 78	 0.175	 0.288	
ZNF266	 2	 54	 0.236	 0.367	
HTR3D	 2	 60	 0.3035	 0.433	
ICAM3	 1	 20	 0.315	 0.433	
BCLAF1	 4	 393	 0.3249	 0.433	
ARHGEF16	 3	 100	 0.4329	 0.551	
CUX1	 1	 39	 0.5141	 0.626	
CPZ	 2	 196	 0.5867	 0.684	
	 119	
PANX3	 2	 120	 1	 1	
WDR25	 2	 126	 1	 1	
ERCC4	 3	 202	 1	 1	























































c.467G>T	 p.Arg156Leu	 3	 2.8	 0	 0/0.5/0.4	
c.481G>A	 p.Glu161Lys	 3	 5.6	 0.5	 2.0/0.7/1.0	
c.6791A>G	 p.Glu2264Gly	 6	 0.5	 0	 not	seen	







































p.R156L	 rs138756085	 C	 D	 D	 D	 N	 D	 5.18	
p.E161K	 rs114161831	 C	 D	 D	 D	 D	 T	 4.94	
p.E2264G	 n/a	 C	 D	 P	 N	 D	 T	 3.71	








































Case	 1.II.1	 2.II.1	 3.III.2	 4.III.1	 5.II.1	 6.II.1	 7.III.5	 8.III.2	 9.II.4	 10.II.1	
Clinical	data	at	1st	assessment:	
Sex	 M	 M	 M	 M	 M	 M	 M	 F	 M	 M	
Age	(yrs)	 14.76	 15.5	 15.5	 16.01	 15.69	 13.66	 16.14	 12,18	 13.55	 14.94	
Bone	age*	 12.5	 12.5	 13.5	 13.5	 13,0	 12.5	 13	 10,0	 -	 -	
Tvol	 2,0/2,0	 2,0/2,0	 4,0/4,0	 2,0/2,0	 2,0/2,0	 2,0/2,0	 2,0/2,0	 	 2.0/2.0	 2.0/2.0	
Ph,	G	or	B	
stage	
1,1	 1,1	 1,2	 2,1	 1,1	 1,1	 1,1	 1,1	 1,1	 1.1	

























-	 144	 121	 98	 112	 -	 -	 	 168	 155	
Age	at:	
G2	or	B2	 15.2	 15.6	 15.5	 16.5	 16,10	 15.21	 16.5	 13.94	 15.21	 15.4	

















PHV	 15.6	 16.2	 17	 17.3	 16,2	 16.18	 17.3	 14.68	 16.1	 16.4	
Induction	of	puberty:	
	 yes	 no	 no	 yes	 yes	 yes	 yes	 no	 no	 no	
Age	at	
start	
14.76	 	 	 16.11	 15,59	 15.21	 16.5	 	 	 	
Duration	
(months)	



































































1.II.1	 M	 p.Arg156Leu	 -1.1	 -1.3	 -0.4	 -0.2	 0.7	 0.9	
2.II.1	 M	 p.Arg156Leu	 -0.2	 -0.4	 -0.7	 -0.2	 -0.5	 -0.3	
3.III.2	 M	 p.Glu161Lys	 -0.5	 -0.8	 0.7	 -0.3	 1.2	 1.5	
4.III.1	 M	 p.Glu161Lys	 -0.4	 -0.7	 0.4	 -0.3	 0.8	 1.1	
5.II.1	 M	 p.Glu161Lys	 -0.3	 -0.2	 0.9	 0.1	 1.2	 1.1	
6.II.1	 M	 p.Glu161Lys	 -0.2	 0	 1.7	 0.2	 1.9	 1.7	
7.III.5	 M	 p.Asp2614Asn	 -1	 -1.5	 -0.4	 -0.5	 0.6	 1.1	
8.III.2	 F	 p.Asp2614Asn	 -1.9	 -2.2	 -1	 -0.3	 0.9	 1.2	
9.II.4	 M	 p.Asp2614Asn	 -0.7	 -1.6	 -0.2	 -0.9	 0.5	 1.4	

















	 n=18	 n=64	 	
Birth	weight	(kg)	 3.6±0.6	 3.7±0.4	 ns	
Birth	length	(cm)	 50.6±1.9	 50.9±1.2	 ns	
Age	at	G2	stage	(yrs)	 15.2±0.8	 15.2±0.9	 ns	
Age	at	“take	off”	(yrs)	 15.0±1.3	 14.9±0.7	 ns	
Age	at	PHV	(yrs)	 16.3±1.2	 16.1±1.0	 ns	











	 n=10	 n=125	 	
Birth	weight	(kg)	 3.7±0.2	 3.6±0.5	 ns	
Birth	length	(cm)	 50.3±2.3	 50.0±2.2	 ns	
Age	at	B2	stage	(yrs)	 13.5±1.0	 13.8±1.0	 ns	
Age	at	“take	off”	(yrs)	 13.3±0.7	 12.5±1.1	 ns	
Age	at	PHV	(yrs)	 14.5±0.7	 13.4±1.0	 ns	
























































































































































































































































































































































































































































































































































111 individuals (18 families, 76 with self-limited DP & 35 controls)
8,289,560 variants
2,474,145 variants
2076 variants in 1765 genes 
41 variants in 28 genes prioritised
28 genes in additional 288 individuals (42 families, 178 with DP, 110 
unaffected)
1 gene (HS6ST1) with 1 variant in 1 family
1 gene (HS6ST1) with 1 pathogenic variant in 
1 family validated
190,979 variants






Segregation with trait 
126,626  variants
‘Multiple family’ filtering 
Targeted exome 
sequencing 
Rare variant burden 
testing
Screening of 100 further 
cohort controls
Functional annotation of 
variants
125 variants in 78 genes
Biological relevance 
filtering
3 genes (IGSF10, 

































































































































































































































































































































































111 individuals (18 families, 76 with self-limited DP & 35 controls)
8,289,560 variants
2,474,145 variants
2076 variants in 1765 genes 
16 variants in 11 genes prioritised
11 genes in additional 288 individuals (42 families, 178 with DP, 110 
unaffected)
2 genes (FTO, LGR4) with variants not 
present in controls
1 gene (FTO) with 1 pathogenic variant in 2
families validated
190,979 variants






Segregation with trait 
126,626  variants
‘Multiple family’ filtering 
Targeted exome 
sequencing 
Rare variant burden 
testing
Screening of 100 further 
cohort controls
Functional annotation of 
variants
125 variants in 78 genes
GWAS relevance 
filtering
2 genes (SEC24A, 
ZNF560) with 


























































SEC24A	 3	 17	 0.0051	 0.029	
ZNF560	 2	 6	 0.00823	 0.038	
LGR4		 8	 172	 0.0155	 0.058	
FTO	 3	 29	 0.0188	 0.058	
SETBP1	 2	 25	 0.0829	 0.155	
TBX6	 4	 102	 0.1204	 0.211	
ZNF266	 2	 54	 0.236	 0.367	
HTR3D	 2	 60	 0.3035	 0.433	
ICAM3	 1	 20	 0.315	 0.433	
WDR25	 2	 126	 1	 1	
























































































































































1.II.1	 M	 p.Ala163Thr	 -	 1.1	 1.7	 16.9	
1.III.2	
(P)	
M	 p.Ala163Thr	 1.1	 0.5	 1.1	 17.1	
1.III.1	 F	 p.Ala163Thr	 0.9	 1.0	 1.1	 17.3	
1.II.5	 M	 p.Ala163Thr	 -1.0	 -1.0	 -0.4	 -	
2.III.5	
(P)	
M	 p.Leu44Val	 -0.9	 -1.4	 -1.5	 18.8	
2.III.6	 M	 p.Leu44Val	 -1.1	 -1.3	 -	 -	
2.II.2	 M	 p.Leu44Val	 -	 -0.8	 -0.8	 20.5	
2.III.1	 M	 p.Leu44Val	 0	 -1.4	 -	 -	
3.II.2	 M	 p.Leu44Val	 -	 -1.0	 -0.9	 18.6	
3.III.2	
(P)	
M	 p.Leu44Val	 -0.9	 -1.1	 -1.3	 18.7	
3.II.3	 M	 p.Leu44Val	 	 -0.4	 -0.1	 22.7	








































































































































































































































































Case	 III.2	(proband)	 II.2	 II.3	 II.4	 III.1	
Age,	yr	 33	 72	 70	 56	 35	
Gender,	M/F	 M	 F	 M	 M	 M	
Pubertal	
development1	
	 	 	 	 	
Genital	stage	2	 16.02yrs	 n.a.	 -	 -	 -	
Acceleration	
growth	spurt	
15.43yrs	 -	 -	 >14.1yrs	 14.02yrs	
Peak	height	
velocity	
16.02yrs	 ?4	 ?5	 ?6	 15.5yrs	
Menarche,	age	
(years)	
























14.1	 n.a.	 -	 -	 -	
BMI,	kg/m2	(18.0	–	
25.0)	

































































GNL2	 KDSR	 SCRN2	 ERBB2	
ASPM	 CACNA1E	 NCAN	 CASP8AP2	
GLI2	 BPNT1	 RPA1	 CELF2	
PBX2	 KCNH7	 APOA1BP	 TPM1	
SLCO3A1	 CLASP2	 CNTN5	 CLDN9	
ZC3H3	 ETFDH	 PRIM2	 MADD	
MED27	 FYN	 ZDHHC7	 COL1A2	
LGR4	 PLXNA4	 DPYSL3	 GATA2	
TIMELESS	 DOLK	 SULT1C3	 JPH3	
DNAAF3	 LRRC55	 UHRF1	 GTF3C3	
SKA3	 FAT3	 DSCAM	 SNAP91	





111 individuals (18 families, 76 with self-limited DP & 35 controls)
8,289,560 variants
2,474,145 variants
2076 variants in 1765 genes 
7 variants in 4 genes prioritised
1 gene (LGR4) 
with 3 variants in 4 
families
1 gene (SEMA6A) 












GN11 vs GT1-7 (n=102) 
GnRH:GFP E14 vs E20
(n=677)
Functional annotation of variants underway
97 variants in 63 genes
Biological relevance 
filtering
2 genes (NCAN, 
NEGR1)   
GN11 vs GT1-7 
n=15































































































































































































LGR4	 p.I96V	 C	 D	 B	 D	 D	 T	 6.06	 0.04/8.8x10-5	
LGR4	 p.G363C	 C	 D	 D	 D	 D	 T	 5.98	 1.5/1.4	
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